Copyright Notice
© [2025] Page76. All Rights Reserved.
The copywriting samples provided herein are the original work of Page76 and are protected under applicable copyright laws. These materials are for demonstration purposes only and may not be copied, reproduced, distributed, or used—whether in whole or in part—without express written permission from the author.
Unauthorized use or reproduction of any portion of this content constitutes a violation of copyright and intellectual property rights and may result in legal action.
Page76
____
Our Words At Work
A selection of copywriting samples produced by Page76
Medical
General Practitioner (GP)
Dr. Amina Yusuf is a compassionate family physician committed to whole-person care. With over 15 years of experience, she brings a thoughtful, evidence-based approach to everyday health, chronic condition management, and preventive care—earning the trust of generations within her community practice.
[Word count: 51]
Medical
Bios
Medico-Legal
Promotion
INDEPENDENT MEDICAL ASSESSMENT REPORT
(Prepared for WorkCover / WorkSafe purposes)
Claimant: Mr J. L.
Date of Birth: 14 March 1984
Date of Injury: 14 January 2025
Date of Examination: 3 June 2025
Date of Report: 15 June 2025
Referral Source: M. & Partners Solicitors
Examining Practitioner: Dr S. R., MBBS, FRACGP
AHPRA Registration Number: MED0123456789
Report Purpose: WorkCover Claim – Initial Injury Assessment
1. PURPOSE OF ASSESSMENT
This independent medical assessment has been requested for the purposes of a WorkCover claim. The report assesses the nature and extent of injuries sustained by Mr J. L. in the course of his employment on 14 January 2025, as well as his capacity for work and treatment requirements.
2. BACKGROUND / MECHANISM OF INJURY
Mr L. reports that on 14 January 2025, while working as a delivery coordinator for a logistics company, he was seated in his work vehicle at a red light when it was struck from behind by a third-party vehicle travelling at high speed (~60 km/h). He was wearing a seatbelt and experienced immediate neck and lower back pain.
The incident was reported to his employer and WorkCover claim documentation has been submitted.
3. CURRENT SYMPTOMS (AS REPORTED BY CLAIMANT)
Persistent cervical spine stiffness and discomfort
Lumbar pain, worsened by prolonged sitting or bending
Headaches localised at the base of the skull, described as tension-related
Difficulty sleeping due to pain and disrupted posture
Reduced tolerance for desk-based work
4. MEDICAL HISTORY
No previous history of spinal injury or chronic musculoskeletal conditions
No current comorbidities
No known allergies
No prior WorkCover claims
Non-smoker; occasional alcohol use
5. EMPLOYMENT DETAILS
Mr L. is employed full-time as a delivery coordinator. The role involves vehicle operation, moderate lifting, and prolonged computer use. He returned to work in a reduced capacity one week after the injury but continues to experience difficulty with sitting and repetitive physical tasks.
6. EXAMINATION FINDINGS
Cervical Spine:
Reduced range of motion (flexion and rotation to approx. 70–75%)
Palpable tenderness over trapezius and paraspinal muscles
No neurological deficits
Lumbar Spine:
Mild paraspinal tenderness
Normal posture and gait
Negative straight leg raise
Reflexes, sensation and power normal in both lower limbs
7. DIAGNOSIS
Whiplash-Associated Disorder (WAD Grade II) – Cervical Spine
Lumbar soft tissue strain (muscular)
These injuries are consistent with a low-to-moderate force rear-end collision and represent soft tissue trauma without evidence of radiculopathy or structural damage.
8. CAPACITY FOR WORK
Mr L. is currently fit for modified duties with restrictions including:
No prolonged sitting (>45 minutes without a break)
No repetitive lifting >5kg
Avoidance of bending and twisting tasks
He is not fit for full pre-injury duties at this stage. Anticipated return to full duties within 6–10 weeks with ongoing treatment.
9. TREATMENT AND MANAGEMENT
Recommended:
Physiotherapy (manual therapy and graded exercise program)
Ergonomic review of workstation
Home-based exercise program
Reassess in 6–8 weeks to monitor progress
No further specialist referrals or imaging indicated at this stage.
10. PROGNOSIS
Prognosis is favourable. With appropriate conservative management, Mr L. is expected to recover fully within 3–6 months of injury. No long-term impairment anticipated.
11. CAUSATION
In my clinical opinion, the reported injuries are directly caused by the work-related motor vehicle incident of 14 January 2025. There is no evidence of prior injury or unrelated pathology.
DECLARATION
I confirm that this report is independent and impartial, and that I have no conflict of interest in this matter. I have prepared this assessment in accordance with the Guidelines for the Evaluation of Work-Related Injuries under WorkSafe Victoria protocols.
Signed:
Dr S. R.
MBBS, FRACGP
AHPRA Reg: MED0123456789
15 June 2025
Melbourne, VIC
[Word count: 603]
COMCARE MEDICO-LEGAL PSYCHIATRIC REPORT
(Prepared for the purposes of the Safety, Rehabilitation and Compensation Act 1988)
Examinee: Ms R. F.
Date of Birth: 17 July 1991
Date of Examination: 4 June 2025
Date of Report: 17 June 2025
Referring Party: Mr D. C., A. Legal Group
Examining Psychiatrist: Dr M. T., MBBS, FRANZCP
AHPRA Registration: MED0123456789
Purpose: Independent Psychiatric Assessment – Comcare Claim
1. INTRODUCTION
This independent medico-legal psychiatric report has been prepared at the request of the referring solicitor in accordance with the Safety, Rehabilitation and Compensation Act 1988 (Cth) (SRC Act). The purpose is to evaluate whether Ms R. F. has suffered a psychiatric injury arising out of or in the course of her employment with a Commonwealth employer, the nature and severity of that injury, causation, treatment needs, and work capacity.
2. EMPLOYMENT & INCIDENT HISTORY
Ms F. commenced employment in 2018 as a Finance Officer with a Commonwealth agency (name withheld). She reports that from approximately May 2023, she began experiencing repeated workplace bullying and unreasonable management practices following a change in direct supervision. Specific allegations include:
Frequent public criticism and belittling
Unrealistic performance demands
Being excluded from meetings
Intimidating tone and verbal hostility
She attempted to report these behaviours through internal HR channels, but perceived no corrective action. She remained at work until February 2024, when her GP certified her unfit for duties due to psychological distress. A Comcare claim was lodged shortly thereafter.
3. PSYCHIATRIC HISTORY
No prior mental health diagnosis, treatment, or hospitalisation
No psychiatric medication use prior to 2024
No history of substance misuse
No significant family history of mental illness
4. PRESENTING SYMPTOMS (AT TIME OF ASSESSMENT)
Ms F. reports the following:
Persistent low mood and loss of interest in previously enjoyable activities
Generalised anxiety, with intrusive workplace-related thoughts
Sleep disturbance (difficulty initiating and maintaining sleep)
Avoidance of social and professional interactions
Reduced confidence, hopelessness, and feelings of worthlessness
Panic attacks triggered by thoughts of work or performance pressure
5. MENTAL STATE EXAMINATION
Appearance: Neatly dressed; appropriate grooming
Behaviour: Anxious, cooperative
Speech: Soft, slowed
Mood: “Flat and overwhelmed”
Affect: Constricted
Thought content: No delusions or hallucinations; passive suicidal ideation (no plan)
Cognition: Mild impairment in concentration
Insight and judgement: Intact
Risk: No current active risk, but heightened psychological vulnerability
6. DIAGNOSIS (DSM-5 TR)
F32.1 Major Depressive Disorder, Moderate
F41.1 Generalised Anxiety Disorder
These conditions developed secondary to workplace stressors as reported.
7. CAUSATION
Based on the information provided, clinical interview, and standard psychiatric evaluation, I am of the opinion that Ms F’s psychiatric condition arose out of and in the course of her Commonwealth employment. The temporal relationship, consistent symptom profile, and lack of any pre-existing psychiatric history support a clear causal link between her employment and her psychological injury.
8. REASONABLE MANAGEMENT ACTION
I am not aware of sufficient evidence to conclude that the employer’s conduct falls under the provisions of "reasonable administrative action carried out in a reasonable manner" (per Section 5A of the SRC Act). In my opinion, the managerial behaviours described were excessive, sustained, and psychologically injurious, and likely exceed what would be considered reasonable management.
9. TREATMENT
Current Treatment:
GP-led mental health care plan
Weekly cognitive behavioural therapy sessions
Sertraline 100mg daily (SSRI) commenced in March 2024
Recommended Treatment:
Ongoing psychological therapy with a trauma-informed focus
Continuation of pharmacotherapy (review after 6 weeks)
Psychiatric review in 3 months to evaluate need for medication adjustment
Structured return-to-work support program with psychological monitoring
10. WORK CAPACITY
Ms F. is currently unfit for work in any capacity.
A graded return to suitable employment (non-client-facing, low-stress, with flexibility and remote option) may be considered within 3–6 months, depending on her therapeutic progress. She is not fit to return to the same workplace or under the same supervision.
11. PROGNOSIS
With consistent treatment and workplace modification, Ms F’s prognosis is fair to good. However, full functional recovery may take 12–18 months, and her confidence in public sector roles may remain impaired. Risk of recurrence is moderate in high-stress settings or if prematurely returned to work.
12. PERMANENT IMPAIRMENT (IF REQUESTED)
A permanent impairment assessment under the Comcare Guide (PI Guide for Psychiatric Conditions) has not been conducted during this evaluation. If required, a structured PIRS assessment (Psychiatric Impairment Rating Scale) can be undertaken in a follow-up appointment.
13. DECLARATION
I confirm that I have no actual or perceived conflict of interest in this matter. I have prepared this report in accordance with the Expert Witness Code of Conduct and acknowledge that my duty is to the Court, Tribunal, or instructing authority, not the party instructing me.
Signed:
Dr M. T.
MBBS, FRANZCP
Consultant Psychiatrist
AHPRA Reg: MED012345
17 June 2025
Canberra, ACT
[Word count: 782]
Disclaimer:
All copywriting samples provided are entirely fictional and created for illustrative purposes only. Any resemblance to real persons, living or deceased, is purely coincidental. These samples do not reference, reflect, or draw upon any real medical, legal, or personal data. They have been developed in accordance with ethical standards and data privacy regulations, including the Australian Privacy Principles (APPs) and other applicable laws. No confidential or identifying information has been used or disclosed in their creation.
Specialist – Cardiologist
Dr. Elena Petrova is a board-certified cardiologist focused on preventive heart health and advanced cardiac imaging. With a dual commitment to clinical excellence and patient education, she tailors each treatment plan with precision—ensuring every heartbeat is backed by the best in modern medicine.
[Word count: 49]
Products
You’re Not Alone - Join Our Group Therapy Sessions
At Brightway Medical Centre, we believe in healing through connection. Our new Group Therapy Program is a safe, supportive space where you can share, listen, and grow alongside others who understand what you're going through.
Led by our experienced mental health clinicians, these sessions focus on:
Building emotional resilience
Coping with stress, anxiety, or grief
Strengthening self-awareness and support networks
Whether you're navigating a life transition or simply looking for a space to feel heard, you're welcome here.
Brightway Medical Centre
123 Dawson Street, Newbridge, VIC 1234
Weekly Sessions: Thursdays at 6:30PM
Limited spots available — call (03) 1234 4567 or visit www.brightwayhealth.com.au to register.
Let’s talk, together.
[Word count: 122]
Protect What Matters Most – Get Vaccinated Today!
Join us at Brightway Medical Centre for our Community Vaccine Drive - a simple step that makes a big difference. Whether you're due for your flu shot, booster, or routine immunisations, our friendly healthcare team is here to help you stay protected, informed, and ready for the season.
Walk-ins welcome
Fast, professional service
Safe and suitable for all eligible age groups
Help keep your family, workplace, and community healthy. No out-of-pocket cost for Medicare card holders. Bring a friend, bring the kids - let’s vaccinate for a safer tomorrow.
Brightway Medical Centre
123 Dawson Street, Newbridge, VIC 3184
Saturday 20 July – Sunday 21 July, 9AM–4PM
Book now or walk in: (03) 1234 4567 | www.brightwayhealth.com.au
[Word count: 123]
AeriVue™ Digital Handheld Spirometer
Precision Lung Function Testing. Anywhere. Anytime.
AeriVue™ is a next-generation digital spirometer built for portability, accuracy, and integration into modern clinical workflows. Designed for respiratory clinics, GPs, telehealth providers, and hospital outreach services, AeriVue™ delivers full-function spirometry - wirelessly and in seconds.
Clinical-Grade, Compact & Connected
✔ Full Spirometry Suite – Measures FEV1, FVC, PEF, and more with ATS/ERS-compliant accuracy
✔ Real-Time Results – Instant data on-screen and synced to EMR or cloud dashboards
✔ Bluetooth & USB Connectivity – Compatible with iOS, Android, and desktop systems
✔ Disposable Turbines – Infection control ready with single-use mouthpieces
✔ Battery-Operated & Travel-Ready – Lightweight, durable, and ideal for outreach or home visits
Built for Professional Use
General Practice & Chronic Disease Clinics
Pulmonary & Allergy Specialists
Occupational Health Providers
Rural & Remote Health Services
Asthma & COPD Management Programs
Aged Care & Home-Based Respiratory Monitoring
Improved Compliance, Smarter Monitoring
AeriVue™ empowers clinicians with fast, repeatable testing and longitudinal lung health tracking - without the need for bulky equipment or lab access. Perfect for early intervention, pre/post bronchodilator testing, and ongoing chronic disease reviews.
Bulk Orders, Training & API Integration Available
Available in multi-clinic kits and institutional license packages
Book a demo or request procurement specs: clinical@aerivue.com.au
Explore full specs at www.aerivue.com.au
AeriVue™ - Lung diagnostics that go where your patients are.
[Word count: 219]
Articles
MediSync™ Smart Pill Dispenser
Enhancing Medication Adherence at Scale
MediSync™ is an intelligent, connected pill dispensing solution designed to streamline complex medication regimens, reduce human error, and improve adherence outcomes across patient populations. Ideal for use in primary care, pharmacy programs, aged care facilities, NDIS services, and hospital discharge planning.
Why Providers Choose MediSync™
✔ Automated Multi-Dose Scheduling – Dispenses up to 6 daily doses with programmable timing and secure locking.
✔ Remote Monitoring & Adherence Tracking – Real-time data via the MediSync™ web dashboard or app, ideal for shared care teams and compliance reporting.
✔ Smart Alerts for Missed or Skipped Doses – Reduces medication lapses, double dosing, and hospital readmissions.
✔ Low Touch, High Impact – Designed to support high caseloads with minimal setup time and reliable ongoing performance.
Built for Healthcare Settings
General Practice & Chronic Disease Management Programs
Discharge & Transitional Care Units
Community Pharmacies and MedsCheck programs
Residential Aged Care & Home Care Package providers
NDIS Registered Providers
Mental Health & Substance Use Recovery Programs
Proven Outcomes
In pilot deployments, MediSync™ reduced medication non-adherence by over 60%, improved patient-reported confidence, and lowered avoidable hospitalisations by 1 in 4 within the first 90 days. (Internal Pilot Study, 2024–2025)
Bulk Licensing, Training & Integration Support Available
Clinic packs | Enterprise solutions | OEM branding
Contact our clinical partnerships team at b2b@medisynchealth.com.au
Learn more: www.medisynchealth.com
MediSync™ — Trusted by clinicians. Backed by data. Built for care.
[Word count: 234]
New Approaches to Post-Partum Depression: The Latest Treatments Giving Mothers Hope
By Brightway Medical Centre
July 2025
Post-partum depression (PPD) affects approximately 1 in 7 women in Australia, and it’s more than just “baby blues” - it’s a real, clinical condition that can impact both mother and baby if left untreated (Beyond Blue, 2024). But there is hope: 2025 has brought new treatment options and a deeper understanding of maternal mental health. With early support and a personalised approach, recovery is not only possible - it’s expected.
Here’s what’s new and effective in the treatment of post-partum depression today.
1. Fast-Acting Medication: Brexanolone and Zuranolone
One of the most significant advances is brexanolone, a fast-acting, hospital-administered medication that works on the brain’s GABA receptors - a different pathway from traditional antidepressants. In clinical trials, many women experienced noticeable relief from depressive symptoms within 72 hours (Deligiannidis et al., 2022).
A newer oral version, zuranolone, is also in development and expected to gain TGA approval soon, making rapid symptom relief more accessible.
2. Trauma-Informed Telehealth Counselling
Telehealth therapy has revolutionised access to maternal mental health care, especially for rural and remote parents. Services like PANDA and MumSpace now offer trauma-informed, perinatal-specialist support through video or phone. In 2025, many new mums are choosing flexible telepsychology options over in-person appointments due to convenience, confidentiality, and childcare limitations (Austin et al., 2023).
3. Mother–Infant Bonding Therapy
A key trend in 2025 is recognising that treating PPD isn't just about symptom relief - it's also about rebuilding the parent-infant connection. Therapies like Circle of Security and dyadic play therapy help strengthen attachment and reduce guilt or disconnection often experienced in PPD. These approaches also improve infant outcomes and long-term emotional health (Milgrom & Holt, 2023).
4. Peer Support Programs and Group Therapy
Peer-led support groups have expanded across Australia, both in person and online. Sharing experiences with other parents can reduce isolation and stigma - major contributors to prolonged symptoms. Clinics and hospitals are increasingly incorporating group-based maternal mental health programs into post-natal care plans (Highet et al., 2024).
5. Holistic and Lifestyle Interventions
Mood and physical health are deeply linked, especially after childbirth. New mothers now have access to post-partum lifestyle coaching that includes sleep regulation, nutrition advice, gentle movement, and emotional check-ins. The Mediterranean diet, rich in omega-3s and fibre, has also shown promise in supporting mood during the postnatal period (Jacka et al., 2022).
6. Partner and Family Involvement
PPD doesn’t happen in isolation. In 2025, many clinics are shifting toward family-inclusive therapy, helping partners recognise signs of distress, respond supportively, and share the mental load of new parenting. Studies show outcomes improve when partners are engaged in the recovery journey (Fisher et al., 2022).
Final Thoughts
Post-partum depression can feel overwhelming, but modern care options are compassionate, science-backed, and increasingly accessible. Whether you’re a new mum, a partner, or a loved one trying to help - know that support is available, and recovery is absolutely possible.
At Brightway Medical Centre, our maternal health team offers gentle, personalised support for parents navigating the emotional challenges of early parenthood. You don’t have to do this alone - and you don’t have to wait to feel better.
References
Austin, M. P., Highet, N., & the Expert Working Group. (2023). Mental health care in the perinatal period: Australian clinical practice guideline. COPE. https://www.cope.org.au
Beyond Blue. (2024). Perinatal mental health statistics. https://www.beyondblue.org.au
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., et al. (2022). Brexanolone injection in post-partum depression: Pooled analysis of two phase 3 trials. Lancet Psychiatry, 9(1), 27–36. https://doi.org/10.1016/S2215-0366(21)00412-9
Fisher, J. R., Tran, T., Rowe, H., et al. (2022). Partner-inclusive interventions for preventing postnatal common mental disorders. BMC Psychiatry, 22, 157. https://doi.org/10.1186/s12888-022-03781-z
Highet, N., Stevenson, A. L., Purtell, C., & Coo, S. (2024). Group therapy for mothers with PPD: An Australian model of care. Australian Journal of Mental Health, 33(2), 107–113.
Jacka, F. N., et al. (2022). Nutritional psychiatry: Diet as a modifiable risk factor for perinatal depression. Current Psychiatry Reports, 24(4), 211–219. https://doi.org/10.1007/s11920-022-01312-8
Milgrom, J., & Holt, C. (2023). Infant–mother attachment and maternal mental health: The emerging role of dyadic therapies. Journal of Perinatal & Neonatal Nursing, 37(1), 56–63. https://doi.org/10.1097/JPN.0000000000000651
[Word count: 702]
New Frontiers in Obesity Treatment: A 2025 Guide to What’s Working
By Brightway Medical Centre
July 2025
Obesity is one of Australia’s most pressing public health challenges, affecting over two-thirds of adults and nearly one in four children (Australian Institute of Health and Welfare [AIHW], 2023). But there’s good news: the landscape of obesity treatment is changing rapidly. In 2025, innovative therapies are offering real hope - not just for weight loss, but for long-term health, confidence, and quality of life.
Here’s what’s new, promising, and evidence-backed in the treatment of obesity today.
1. GLP-1 Receptor Agonists (e.g. Semaglutide)
Originally developed for type 2 diabetes, medications like semaglutide (Ozempic®, Wegovy®) have now been approved in Australia specifically for weight management. These drugs work by mimicking a gut hormone that reduces hunger and slows digestion. In clinical trials, patients lost 10–15% of body weight on average over 12–18 months (Wilding et al., 2021). They’re a game-changer for those struggling with appetite regulation.
2. Metabolic Surgery: Safer and More Accessible
Gastric sleeve and bypass procedures remain the most effective long-term treatment for severe obesity, but the process has become safer, faster, and more personalised. Modern bariatric surgery is often performed laparoscopically, with shorter hospital stays and tailored nutritional follow-up. Surgery is now considered for more people - not just those with a BMI over 40, but also individuals with comorbidities like type 2 diabetes or sleep apnoea (Mechanick et al., 2022).
3. Obesity as a Chronic Condition: The Mindset Shift
Perhaps the biggest change is how we view obesity - not as a failure of willpower, but as a complex, chronic condition influenced by genetics, hormones, environment, and psychology. New guidelines encourage long-term, multidisciplinary care, where GPs, dietitians, psychologists, and exercise physiologists work as a team to provide ongoing support (Obesity Collective, 2024).
4. Psychological Therapies: Tackling the “Why”
Behavioural therapy, acceptance and commitment therapy (ACT), and mindful eating practices are being increasingly integrated into obesity care. These approaches go beyond “eat less, move more” and explore emotional triggers, body image, and long-term habits. According to a recent meta-analysis, adding psychological support significantly improves both weight outcomes and mental health (Forman et al., 2022).
5. Wearables & AI Coaching
Smartwatches, glucose monitors, and AI-driven nutrition apps now do more than track steps - they deliver real-time behaviour coaching, alert users to patterns, and can even adjust diet or exercise plans based on feedback. Digital tools like Noom®, Habitual®, and Australian-developed apps like CSIRO Total Wellbeing Diet Online are becoming key tools in long-term success (Torous et al., 2023).
6. Food as Medicine
New research confirms what many clinicians have long suspected: food quality matters. The Mediterranean diet, rich in vegetables, olive oil, legumes, and fish, is being prescribed for its anti-inflammatory and weight-regulating benefits (Jacka et al., 2022). Personalised nutrition, often based on microbiome or genetic testing, is also gaining traction in private practice.
Final Thoughts
The treatment of obesity in 2025 is no longer just about “diet and exercise.” It’s about personalised medicine, psychological support, advanced pharmacology, and sustained behavioural change. At Brightway Medical Centre, we take a whole-person approach to weight management, helping patients move toward better health - one step at a time.
If you or someone you care about is ready to explore new options for managing weight and improving health, we’re here to help.
References
Australian Institute of Health and Welfare. (2023). Overweight and obesity snapshot. https://www.aihw.gov.au/reports-data/behaviours-risk-factors/overweight-obesity/overview
Forman, E. M., Butryn, M. L., Manasse, S. M., Crosby, R. D., & Wyckoff, E. P. (2022). Acceptance-based behavioural treatment for obesity: A review and future directions. Obesity Reviews, 23(1), e13411. https://doi.org/10.1111/obr.13411
Jacka, F. N., O'Neil, A., Itsiopoulos, C., Opie, R. S., Cotton, S., Mohebbi, M., & Berk, M. (2022). A randomised controlled trial of dietary improvement for adults with obesity and low mood (HELFIMED). Nutrients, 14(1), 221. https://doi.org/10.3390/nu14010221
Mechanick, J. I., Apovian, C. M., Brethauer, S., Garvey, W. T., Joffe, A. M., & Aronne, L. J. (2022). Clinical practice guidelines for the perioperative management of metabolic and bariatric surgery patients—2022 update. Obesity (Silver Spring), 30(7), 1187–1215. https://doi.org/10.1002/oby.23452
Obesity Collective. (2024). National Framework for Obesity Care. https://www.obesitycollective.org.au/resources
Torous, J., Firth, J., Huckvale, K., et al. (2023). The emerging role of digital mental and metabolic health technologies. The Lancet Digital Health, 5(2), e90–e98. https://doi.org/10.1016/S2589-7500(23)00014-1
Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
[Word count: 747
